Showing results (1-10 of 699) with videos related to
Sort By:
Pageof 70
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Multiple myeloma: is it time for biomarker-driven therapy?Manisha Bhutani, Ola Landgren, Saad Z UsmaniDrug Design, Development and Therapy|March 31, 2017
Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myelomaReed Friend, Manisha Bhutani, Peter M Voorhees, et al.Seminars in Oncology|May 15, 2016
Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disordersManisha Bhutani, Zainab Shahid, Alicia Schnebelen, et al.Leukemia & Lymphoma|July 7, 2020
Management of newly diagnosed transplant ineligible multiple myelomaShebli Atrash, Manisha Bhutani, Barry Paul, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 28, 2018
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvementJustin R Arnall, Saad Z Usmani, Hawawu Adamu, et al.Expert Opinion on Biological Therapy|August 5, 2020
Daratumumab subcutaneous formulation for the treatment of multiple myelomaBarry Paul, Issam Hamadeh, Shebli Atrash, et al.Expert Review of Hematology|July 14, 2020
An evaluation of subcutaneous daratumumab for the treatment of multiple myelomaBarry Paul, Shebli Atrash, Manisha Bhutani, et al.Leukemia|November 29, 2019
Extramedullary multiple myelomaManisha Bhutani, David M Foureau, Shebli Atrash, et al.Clinical Lymphoma, Myeloma & Leukemia|December 18, 2016
Practical Considerations in Managing Relapsed Multiple MyelomaAmit Agarwal, Eric Chow, Manisha Bhutani, et al.European Journal of Haematology|October 12, 2013
Smoldering multiple myeloma: present position and potential promisesNishant Tageja, Elisabet E Manasanch, Neha Korde, et al.Pageof 70